Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity, Proprietary Technologies Platforms & Clinical Trials Insight 2030

Report Finding & Highlights:

Global & Regional Market Outlook
Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity: > US$1 Billion
Number Of Approved Tumor Infiltrating Lymphocytes Therapy: 1 Therapy
Approved Tumor Infiltrating Lymphocytes Therapy Dosage, Pricing & Sales Insight
Number Of Tumor Infiltrating Lymphocytes Therapies in Clinical Trials: > 30 Therapies
Global Tumor Infiltrating Lymphocyte Therapies Clinical Trials By Company, Indication & Phase
Proprietary Technologies Insight By Companies

Tumor Infiltrating Lymphocytes Therapy Need & Why This Report?

Tumor Infiltrating Lymphocytes Therapy (TIL) therapy has proven to be one of the most promising treatments for solid tumors, particularly in patients who are no longer responsive to conventional treatments like checkpoint inhibitors. In contrast to other conventional immunotherapies, TIL therapy leverages a patient's own tumor infiltrating lymphocytes, already cancer antigen experienced immune cells, to execute a specific, individualized immune response. This treatment is especially relevant for melanoma and other late-stage cancers when alternatives are exhausted and prognoses unfavorable. Recent US approval in February 2024 of Amtagvi (lifileucel), i.e., the only globally approved TIL therapy to date, has moved commercial interest and scientific impetus in the field ahead at an accelerated pace.

This report is intended to give stakeholders a holistic overview of the changing TIL therapy landscape, touching on clinical development, active industry players, technological advancements, and market projections.

Clinical Trials Insight Included In Report

This report investigates the current trend of ongoing and emerging clinical trials and identifies the most promising pipeline candidates that have the potential to be next-generation oncology treatments. Data in this section includes specifically trial stages, sponsors, geographical distribution, technology providers, collaborators and license holders. For example, in China, Bennu Biotherapeutics is running a Phase I trial of BEN-101 in solid tumors under the auspices of the Shanghai Jiao Tong University. In the US, a number of academic institutions and biotechnology companies are conducting early-stage trials extending TIL therapy to indications such as cervical, lung, and head and neck cancers. The data indicate an increasing global interest in TIL research, with the US, China, Australia, and regions of Europe leading trial activity.

Leading Companies Engaged In R&D Of Tumor Infiltrating Lymphocytes Therapy

Apart from Iovance Biotherapeutics, the global standard setter with its lifileucel product, other players such as Juncell Therapeutics (China), Biosyngen (Singapore), SunAct Cancer Institute (India), and Instil Bio (US) are also seriously involved in TIL R&D. These companies are not merely trying to broaden the therapeutic applications of TIL therapy but also to overcome the several key challenges in scalability, affordability, and access to patients. Academic research hospitals like the National Cancer Centre Singapore and Loma Linda University Cancer Center in the US are also playing active roles through funded pilot programs and institutional partnerships.

Technology Platforms, Collaborations & Agreements

The report indicates a trend towards unified technology platforms that simplify the TIL therapy life cycle. Creative Biolabs, for example, provides an end-to-end platform for the profiling of tumor neoantigens and expansion of TILs. Additionally, Xcell Biosciences Australia has partnered with Royal Perth Hospital to establish an automated production process through the AVATAR™ Foundry system.

Numerous licensing deals and cross-border collaborations are also accelerating innovation, such as the partnership between Malaysia’s Abgentil Biomedical and India’s SunAct Cancer Institute to localize manufacturing and access.

Report Indicating Future Direction Of Tumor Infiltrating Lymphocytes Therapy Segment

From trial results, company activity, and investment in infrastructure, the report determines that the TIL therapy market is poised for explosive growth. As Amtagvi became the first proven product, the market now is transitioning from academic and experimental to more extensive clinical use and commercialization. Important future trends are shorter manufacturing times, growth into non-melanoma indications, regional manufacturing centers, and middle-income country pricing models.

The coming years are expected to witness a shift from an individual-product market to a multi-player, competitive ecosystem providing various TIL solutions globally.

1. Tumor Infiltrating Lymphocytes (TIL): A Brief Introduction

1.1 Overview
1.2 TIL History & Concept

2. Emergence Of Tumor Infiltrating Lymphocytes Therapy

2.1 Tumor Infiltrating Lymphocytes As Prognostic Biomarkers
2.2 Tumor Infiltrating Lymphocytes Therapy Combinational Approach

3. Amtagvi - First Approved Tumor Infiltrating Lymphocyte Therapy

3.1 Overview & Patent Insight
3.2 Dosage & Price Analysis
3.3 Sales Analysis

4. Global Tumor Infiltrating Lymphocytes Therapy Market Overview

4.1 Current Market Scenario
4.2 Future Opportunities

5. Tumor Infiltrating Lymphocytes Therapy Development Trends By Region

5.1 US
5.2 Canada
5.3 China
5.4 UK
5.5 EU

6. Tumor Infiltrating Lymphocytes Therapy Approaches By Cancer

6.1 Melanoma
6.2 Lung Cancer
6.3 Breast Cancer
6.4 Gastrointestinal Cancers (Colorectal Cancer, Gastric Cancer, Pancreatic
Cancer, Hepatocellular Carcinoma)
6.5 Gynecological Cancers (Ovarian Cancer, Uterine/ Endometrial Cancer, Cervical
Cancer)
6.6 Genitourinary Cancers (Bladder/Urothelial Carcinoma, Renal Cell, Prostate
Cancer)
6.7 Head & Neck Cancers
6.8 Brain Cancers

7. Global Tumor Infiltrating Lymphocytes Therapy Market Dynamics

7.1 Market Drivers & Opportunities
7.2 Market Challenges & Restraints

8. Global Tumor Infiltrating Lymphocytes Therapy Trials Overview

8.1 By Breakthrough & Fast Track Status
8.2 By Country
8.3 By Company
8.4 By Indication
8.5 By Phase
8.6 By Orphan Status

9. Global Tumor Infiltrating Lymphocyte Therapies Clinical Trials By Company, Indication & Phase

9.1 Research
9.2 Preclinical
9.3 Phase-0
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III

10. Marketed Tumor Infiltrating Lymphocyte Therapies Clinical Pipeline By Company, Indication & Phase11. Tumor Infiltrating Lymphocytes Therapy Proprietary Technologies Insight By Companies

12. Competitive Landscape

12.1 Adaptimmune
12.2 AgonOx
12.3 GRIT Biotechnology
12.4 ImmuneCyte
12.5 Intima Bioscience
12.6 Iovance Biotherapeutics
12.7 Juncell Therapeutics
12.8 Leman Biotech
12.9 Obsidian Therapeutics
12.10 RootPath

List of Tables

Table 1-1: TIL Therapy vs Conventional Therapies
Table 1-2: TIL Presence In Different Cancers
Table 1-3: Improvements Over Time In TIL Manufacturing
Table 1-4: TIL Manufacturing Process - Traditional & Modern TIL Production Protocols
Table 2-1: TIL Therapy vs CAR-T Therapy
Table 2-2: Key Prognostic TIL Subtypes & Their Functions
Table 2-3: Tumor Microenvironment Transformation By Combination Therapy
Table 2-4: Combinational Approaches In TILs For Different Cancer Indications
Table 3-1: Global Regulatory Status Of Amtagvi

List of Figures

Figure 1-1: Procedure Of Tumor Infiltrating Lymphocytes Therapy
Figure 1-2: Phenotypic Composition of TILs
Figure 1-3: Components Of Rapid Expansion Protocol
Figure 1-4: Historical Evolution Of TIL Therapy
Figure 2-1: Advantages Of TIL Therapy
Figure 2-2: TILs As Biomarkers
Figure 2-3: Combination Strategies To Boost TIL Therapy
Figure 3-1: Amtagvi - Approval Year by Region
Figure 3-2: Amtagvi - US Patent/Application Information
Figure 3-3: Amtagvi - Global Annual Sales (US$ Million), 2024-2025
Figure 3-4: Amtagvi - Global Quarterly Sales (US$ Million), Q1 & Q2’2025
Figure 3-5: Amtagvi - Global Quarterly Sales (US$ Million), Q2-Q4’2024
Figure 4-1: Global - Tumor Infiltrating Lymphocytes Therapy Market (US$ Million), 2024 & 2025
Figure 4-2: Global Tumor Infiltrating Lymphocyte Therapy Market - Future Opportunities
Figure 4-3: Global - Tumor Infiltrating Lymphocytes Therapy Market (US$ Million), 2029 - 2030
Figure 6-1: NCI-2022-06873 Phase I (NCT05470283) Study - Initiation & Estimated Completion Year
Figure 6-2: NCI-2022-06873 Phase I (NCT05470283) Study - Initiation & Estimated Completion Year
Figure 6-3: MM2319 Phase I (NCT06204991) Study - Initiation & Estimated Completion Year
Figure 6-4: TILVANCE-301 Phase III (NCT05727904) Study - Initiation & Estimated Completion Year
Figure 6-5: BaseTIL-03M Phase I (NCT05869539) Study - Initiation & Estimated Completion Year
Figure 6-6: NCI-2012-01368 Phase II (NCT00338377) Study - Initiation & Estimated Completion Year
Figure 6-7: MCC-21971 Phase I (NCT05681780) Study - Initiation & Estimated Completion Year
Figure 6-8: 14-C-0104 Phase II (NCT02133196) Study - Initiation & Estimated Completion Year
Figure 6-9: IOV-COM-202 Phase II (NCT03645928) Study - Initiation & Estimated Completion Year
Figure 6-10: IOV-LUN-202 Phase II (NCT04614103) Study - Initiation & Estimated Completion Year
Figure 6-11: IOV-GM1-201 Phase I/II (NCT05361174) Study - Initiation & Estimated Completion Year
Figure 6-12: CCI-2005 Phase I (NCT05676749) Study - Initiation & Estimated Completion Year
Figure 6-13: MCC-21971 Phase I (NCT05681780) Study - Initiation & Estimated Completion Year
Figure 6-14: CheckCell-2 Phase I/II (NCT05566223) Study - Initiation & Estimated Completion Year
Figure 6-15: TIL-2021001 Phase I (NCT05366478) Study - Initiation & Estimated Completion Year
Figure 6-16: ITIL-306-201 Phase I (NCT05397093) Study - Initiation & Estimated Completion Year
Figure 6-17: 14-C-0104 Phase II (NCT02133196) Study - Initiation & Estimated Completion Year
Figure 6-18: TILS001 Phase I/II (NCT05451784) Study - Initiation & Estimated Completion Year
Figure 6-19: GC101-21K177 Phase I (NCT05142475) Study - Initiation & Estimated Completion Year
Figure 6-20: Phase I (NCT05505812) Study - Initiation & Estimated Completion Year
Figure 6-21: ZZTIL-012 Phase I (NCT04842812) Study - Initiation & Estimated Completion Year
Figure 6-22: 10-C-0166 Phase II (NCT01174121) Study - Initiation & Estimated Completion Year
Figure 6-23: 2019LS002 Phase I (NCT04426669) Study - Initiation & Estimated Completion Year
Figure 6-24: NCI-2024-07763 Phase I/II (NCT06598371) Study - Initiation & Estimated Completion Year
Figure 6-25: Phase I (NCT04766320) Study - Initiation & Estimated Completion Year
Figure 6-26: GC203-1.0 Phase II (NCT05468307) Study - Initiation & Estimated Completion Year
Figure 6-27: GC201-1.0 Phase I (NCT05098171) Study - Initiation & Estimated Completion Year
Figure 6-28: 10-C-0166 Phase II (NCT01174121) Study - Initiation & Estimated Completion Year
Figure 6-29: NCI-2018-00918 Phase II (NCT03449108) Study - Initiation & Estimated Completion Year
Figure 6-30: XHKT-SCT006-2022 Phase II (NCT05342506) Study - Initiation & Estimated Completion Year
Figure 6-31: TIL-2021001 Phase I (NCT05366478) Study - Initiation & Estimated Completion Year
Figure 6-32: C-145-04 Phase II (NCT03108495) Study - Initiation & Estimated Completion Year
Figure 6-33: NCI-2024-08121 Phase II (NCT06626256) Study - Initiation & Estimated Completion Year
Figure 6-34: MCC-21894 Phase I (NCT05768347) Study - Initiation & Estimated Completion Year
Figure 6-35: ITIL-306-201 Phase I (NCT05397093) Study - Initiation & Estimated Completion Year
Figure 6-36: IOV-COM-202 Phase II (NCT03645928) Study - Initiation & Estimated Completion Year
Figure 6-37: NCI-2018-00918 Phase II (NCT03449108) Study - Initiation & Estimated Completion Year
Figure 6-38: GC101-JD-LK Phase I (NCT04943913) Study - Initiation & Estimated Completion Year
Figure 6-39: BAH2472 Phase I/II (NCT06626256) Study - Initiation & Estimated Completion Year
Figure 7-1: Global Tumor Infiltrating Lymphocyte Therapy Market - Drivers & Opportunities
Figure 7-2: Global Tumor Infiltrating Lymphocyte Therapy Market - Challenges & Strategic Solutions
Figure 8-1: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Priority Status, 2025 Till 2030
Figure 8-2: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Country, 2025 Till 2030
Figure 8-3: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Company, 2025 Till 2030
Figure 8-4: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Indication, 2025 Till 2030
Figure 8-5: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Phase, 2025 Till 2030
Figure 8-6: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Orphan Status, 2025 Till 2030
Figure 11-1: Iovance Biotherapeutics - TIL Therapy Platform
Figure 11-2: Iovance Biotherapeutics - Streamlined 22-day GMP Manufacturing Process
Figure 11-3: Obsidian Therapeutics - cytoDRiVE Platform
Figure 11-4: Novoleucel Steps Involved

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Adaptimmune
AgonOx
GRIT Biotechnology
ImmuneCyte
Intima Bioscience
Iovance Biotherapeutics
Juncell Therapeutics
Leman Biotech
Obsidian Therapeutics
RootPath

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2672EUR$3,000USD£2,325GBP
Hard Copy	A printed copy of the product will be shipped to you.		€3831EUR$4,300USD£3,333GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4365EUR$4,900USD£3,798GBP

Report Finding & Highlights:

Tumor Infiltrating Lymphocytes Therapy Need & Why This Report?

Clinical Trials Insight Included In Report

Leading Companies Engaged In R&D Of Tumor Infiltrating Lymphocytes Therapy

Technology Platforms, Collaborations & Agreements

Report Indicating Future Direction Of Tumor Infiltrating Lymphocytes Therapy Segment

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Tumor-Infiltrating Lymphocyte Therapy Market - Global Forecast 2025-2030

Tumor Infiltrating Lymphocytes Market Report 2025

TIL Therapy - Pipeline Insight, 2025

LAG-3 Targeting Therapy Market, Drug Dosage, Patent, Sales & Clinical Trials Insight 2030 Report

Peptide Cancer Vaccine Market Opportunity, Technology Platforms & Clinical Trials Insight 2030